These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18195670)

  • 1. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices.
    Giovannoni G; Kinkel P; Vartanian T
    Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of Tysabri: international risk management plan.
    Iaffaldano P; D'Onghia M; Trojano M
    Neurol Sci; 2009 Oct; 30 Suppl 2():S159-62. PubMed ID: 19882366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Natalizumab (Tysabri)].
    Ravnborg M
    Ugeskr Laeger; 2007 Sep; 169(38):3184-7. PubMed ID: 17910826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC;
    Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA; Rivey MP; Allington DR
    Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Natalizumab in multiple sclerosis].
    Rajda C; Bencsik K; Vécsei L;
    Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract]   [Full Text] [Related]  

  • 16. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natalizumab in multiple sclerosis].
    Río-Izquierdo J; Montalban X
    Rev Neurol; 2009 Sep 1-15; 49(5):265-9. PubMed ID: 19714558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.
    Castela E; Lebrun-Frenay C; Laffon M; Rocher F; Cohen M; Leccia NC; Bahadoran P; Lacour JP; Ortonne JP; Passeron T
    Arch Dermatol; 2011 Jan; 147(1):72-6. PubMed ID: 20855675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab. Elan/Biogen.
    Elices MJ
    Curr Opin Investig Drugs; 2003 Nov; 4(11):1354-62. PubMed ID: 14758775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ; Munday JR
    Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.